tetano
Editor, Senior Moderator
Clin Infect Dis
. 2021 May 6;ciab409.
doi: 10.1093/cid/ciab409. Online ahead of print.
Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality
Pranay Sinha[SUP] 1 [/SUP], Benjamin P Linas[SUP] 1 [/SUP]
Affiliations
Abstract
Recent randomized trials suggest that interleukin-6 inhibitors like tocilizumab have mortality benefit for patients with severe coronavirus disease-2019. We employed a decision tree to investigate their cost-effectiveness and found that tocilizumab is cost-effective with an estimated incremental cost-effectiveness ratio of $16520 per quality-adjusted life year gained (95% credible interval 10760-51530).
. 2021 May 6;ciab409.
doi: 10.1093/cid/ciab409. Online ahead of print.
Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality
Pranay Sinha[SUP] 1 [/SUP], Benjamin P Linas[SUP] 1 [/SUP]
Affiliations
- PMID: 33956936
- DOI: 10.1093/cid/ciab409
Abstract
Recent randomized trials suggest that interleukin-6 inhibitors like tocilizumab have mortality benefit for patients with severe coronavirus disease-2019. We employed a decision tree to investigate their cost-effectiveness and found that tocilizumab is cost-effective with an estimated incremental cost-effectiveness ratio of $16520 per quality-adjusted life year gained (95% credible interval 10760-51530).